Skip to main content

Table 4 Prognostic analysis of DFS and OS for GISTs of the small intestine in terms of immunohistochemical features

From: Surgical treatment and prognostic analysis for gastrointestinal stromal tumors (GISTs) of the small intestine: before the era of imatinib mesylate

Variable

 

Mean DFS (ms; 95%CI of mean)

P

Mean OS (ms; 95%CI of mean)

P

CD117 (KIT)

Focally positive (N = 12)

40.1 (18.3–61.9)

0.1276

77.8 (39.9–115.6)

0.2159

 

Diffusely positive (N = 73)

74.4 (54.0–94.7)

 

101.6 (79.1–124.3)

 

KIT immunopattern

Diffuse cytoplasmic stain (N = 55)

80.8 (54.6–107.0)

0.0981

95.5 (70.9–120.1)

0.8628

 

Mixed with "golgi pattern" (N = 30)

51.6 (33.1– 70.1)

 

99.4 (69.1–129.7)

 

CD34

Negative (N = 25)

64.8 (44.9–84.6)

0.4806

87.5 (64.7–110.4)

0.2242

 

Focally positive (N = 28)

55.9 (34.6–77.2)

 

70.6 (48.2–93.0)

 
 

Diffusely positive (N = 32)

81.0 (50.6–111.4)

 

116.9 (84.4–149.2)

 

SMA

Negative (N = 36)

76.3 (44.4–108.3)

0.1866

101.2 (70.5–132.0)

0.0637

 

Focally positive (N = 17)

45.4 (24.3– 66.5)

 

56.8 (34.6–78.9)

 
 

Diffusely positive (N = 32)

82.0 (60.7–103.2)

 

106.8 (82.2–131.4)

 

S-100

Negative (N = 34)

81.9 (49.9–113.9)

0.1274

104.9 (75.8–133.9)

0.3896

 

Focally positive (N = 31)

64.5 (44.6–84.5)

 

79.8 (60.6–99.0)

 
 

Diffusely positive (N = 20)

48.4 (22.43–74.3)

 

78.6 (43.4–113.9)

 

Ki-67 index

< 10% (N = 80)

73.6 (53.9–93.4)

0.0014

99.4 (78.5–120.2)

0.0171

 

10% (N = 5)

13.8 (6.8–20.8)

 

24.0 (13.0–35.0)

 
  1. DFS = disease-free survival; OS = overall survival; GISTs = gastrointestinal stromal tumors